Abstract 1333
Background
Patients with IIIA-pN2 non-small cell lung cancer (NSCLC) are a heterogeneous group, So this meta-analysis aimed to determine prognostic factors and compare different postoperative adjuvant therapies on survival.
Methods
MEDLINE, Embase, Web of Science were searched to identify relevant trials up to May 2017. Datas of univariate and multivariate analyses of prognostic factors for overall survival (OS) were extracted and calculated by hazard ratios (HR) and 95% confience intervals (95% CI). Pooled survival curves were constructed by Engauge Digitizer and RStudio.
Results
Overall 26 trials comprising 11,384 patients were included. The subgroup analysis for OS indicated that increased age (HR 1.02, 95%CI 1.02-1.02, P < 0.00001), male (HR 1.37, 95%CI 1.25–1.49, P < 0.00001), increased pathologic T stage (HR 1.27, 95%CI 1.12–1.45, P = 0.0003), multiple N2 metastases (HR 1.53, 95%CI 1.34–1.74, P < 0.0001), positive of skip matestasis (HR 2.07, 95%CI 1.25–3.42, P < 0.0001), involvement of N1 nodal station (HR 1.42, 95%CI 1.13–1.70, P = 0.003), pneumonectomy (HR 1.42, 95%CI 1.16–1.73, P = 0.0007), increasing clinical T classification (HR 1.48, 95%CI 1.09–2.02, P = 0.01), increasing clinical N classification (HR 1.75, 95%CI 1.23–1.48, P = 0.002) were significantly associated with poor OS and N downstaging (HR 0.46, 95%CI 0.37–0.68, P < 0.0001), PORT (HR 0.76, 95%CI 0.64–0.72, P = 0.004), adjuvant chemotherapy (HR 0.69, 95%CI 0.56–0.85, P = 0.007) were significantly associated with better OS. The 5-year disease-free survival rate was 38.9% in postoperative chemoradiotherapy group and 29.5% in postoperative chemotherapy group (p = 0.001). Survival was improved in patients with pN2 disease who received postoperative radiotherapy, both in the chemotherapy (5-year survival rate, 65.3% vs. 49.3%) and observation arm (5-year survival rate, 53.3% vs. 32.3%).
Conclusions
The main prognostic factors were age, gender, clinical T stage, pathologic T stage, operation procedure, clinical N status, involved N2 stations, N1 nodes involved, N2 Skip metastasis, N downstaging, postoperative radiotherapy as well as adjuvant chemotherapy. And these should be considered as stratification factors for further trials.
Clinical trial identification
Legal entity responsible for the study
Key Laboratory of Cancer Proteomics of Chinese Ministry of Health, Xiangya Hospital, Central South University.
Funding
China “863” Plan Project.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5877 - TCR beta chain convergence defines the tumor infiltrating T cell repertoire of melanoma and non-small cell lung carcinoma.
Presenter: Timothy Looney
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3212 - PI3K inhibition and modulation of immune and tumor microenvironment markers by copanlisib in patients with non-Hodgkin's lymphoma or advanced solid tumors
Presenter: Ahmad Awada
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3574 - Pan-squamous genomic profiling stratified by anatomic tumor site and viral association
Presenter: Meagan Montesion
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4113 - Toward the Standardization of Bioinformatics Methods for the Accurate Assessment of Tumor Mutational Burden (TMB)
Presenter: Han Chang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4468 - Prediction of primary resistance to anti-PD1 therapy (APD1) in 2nd line NSCLC
Presenter: Egbert Smit
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4570 - Immunomodulatory germline variation impacts the development of multiple primary melanoma (MPM).
Presenter: Robert Ferguson
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1169 - Leukocyte telomere length and recurrence risk after EGFR-TKIs therapy in patients with advanced lung adenocarcinoma
Presenter: Ming Yang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1707 - Gene embedding: a novel machine learning approach to identify gene candidates related to immunotherapy responsiveness
Presenter: Chi Tung Choy
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2123 - Common and rare DPYD variants are predictive for 5FU/capecitabine (5FU) toxicity: The MRC COIN and COIN-B trials
Presenter: Ayman Madi
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5671 - The landscape of NTRK fusions in Chinese solid tumor patients
Presenter: Qi Ling
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract